March 22, 2026 · Journal of hepatology · DOI: 10.1016/j.jhep.2026.03.019

Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative

Listen to this summary

The authors aimed to evaluate the feasibility and clinical impact of comprehensive genomic profiling in patients with advanced primary liver cancers (PLC) who are refractory to systemic treatments. They found that nearly two-thirds of the patients had actionable genomic alterations, leading to disease control in a subset of those treated with matched therapies. This study underscores the potential of genomics-guided strategies to enhance personalized treatment options and improve outcomes for patients with hepatobiliary malignancies.

C Campani, P Laurent Puig, F Villeret, Y Benmerabet, J Netter, Y Chouik, E Spitzer, P Merle, G Bousquet, M Ziol, A Asif-Laidin, O Seror, N Ganne-Carrie, P Nahon, A Ait Omar, L Marisa, M Lequoy, M Bouattour, C Tlemsani, M Ningarhari, M Allaire, J Zucman-Rossi, J C Nault

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play